CompoAtlas

Genestra Brands Femagen PMS Capsules

Genestra Brands Femagen PMS Capsules, NPN 80023503: natural health product licensed in Canada. Medicinal ingredients: Choline, Zinc, Riboflavine, Folate.

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Choline

Source : Bitartrate de choline

15 mgNot calculated
Zinc

Source : Citrate de zinc

5 mg10,000 µg
Riboflavine

Source : Riboflavine

10 mg20,000 µg
Folate

Source : Acide folique

200 mcgNot calculated
Magnésium

Source : Citrate de magnésium

60 mg120,000 µg
Dioscorea villosa

Source : Extrait de racine

Extraction ratio : 10:1

Dry plant equivalent : 200 mg

20 mgNot calculated
Vitex agnus-castus

Source : Fruit

15 mgNot calculated
Thiamine

Source : Mononitrate de thiamine

10 mg20,000 µg
Calcium

Source : Citrate de calcium tétrahydraté

30 mg60,000 µg
Calcium

Source : Carbonate de calcium

30 mg60,000 µg
Arctostaphylos uva-ursi

Source : Feuille

15 mgNot calculated
Petroselinum crispum

Source : Parties aériennes

20 mgNot calculated
Eleutherococcus senticosus

Source : Racine

Extraction ratio : 10:1

Dry plant equivalent : 150 mg

15 mgNot calculated
Niacine

Source : Inositol nicotinate

9 mgNot calculated
Vitamine E

Source : D-alpha-tocophéryl succinate

Potency : 50 UI

34 mg EATNot calculated
Acide pantothénique

Source : D-Pantothénate de calcium

25 mg50,000 µg

Non-medicinal ingredients

Stéarate de magnésium, Hypromellose, silice, Microcrystalline cellulose

PopulationAgeQuantity per servingFrequency
AdultesNot specified1 Capsule2 Tous les jours

Uses authorised in Canada

For relief of symptoms associated with premenstrual syndrome. Used in Herbal Medicine to help relieve premenstrual symptoms Used in Herbal Medicine (as a hormone normaliser) to help stabilise menstrual cycle irregularities. Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flushes. Used in Herbal Medicine (as a hormone normaliser) to help stablilise menstrual cycle irregularities and relieve premenstrual symptoms. Helps to form red blood cells. Helps to maintain normal red blood cells. Helps normal growth and development. Helps in energy metabolism and tissue formation. A factor in the maintenance of good health and normal growth and development. Helps to main the body¿s ability to metabolize nutrients. Helps to maintain healthy mucous membranes. Helps to maintain normal metabolism of iron. Helps in energy production. Supports energy production. Helps in the normal function of the immune system. Helps to maintain healthy metabolism. Source of/An antioxidant for the maintenance of good health. Antioxidant for good health. Source of/An antioxidant that protects the fat in body tissues from oxidation. Source of/An antioxidant that helps (to): a) fight/ b) protect (cells) against / c)reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Helps in the development and maintenance of bones and teeth. Helps in tissue formation. Helps to maintain (proper) muscle function. 24) Helps in the development and maintenance of bones and teeth and maintain proper muscle function and tissue formation. Helps to maintain proper muscle function, including the heart muscle. Helps to maintain heart muscle function. Provides/Source of/An electrolyte (for the maintenance of good health). Helps to maintain normal electrolyte balance. Helps in connective tissue formation. Helps to maintain healthy skin. Helps maintain healthy skin and connective tissue formation. Helps (to) maintain/support immune function/system. Helps with immune function. Helps to maintain healthy bones, hair, nail and/or skin. Maintains healthy hair, skin and nails. Provitamin A/Source of vitamin A for the maintenance of good health. Source of vitamin A. Provitamin A/Source of vitamin A to help/helps maintain eyesight, skin, membranes and immune function. Provitamin A/Source of vitamin A to help/helps in the development and maintenance of night vision. Provitamin A/Source of vitamin A to help/helps in the development and maintenance of bones and teeth. Provitamin A/Source of vitamin A to help/helps maintain eyesight, skin, membranes and immune function and helps in the development and maintenance of night vision, bones and teeth. Helps to support liver function Helps to prevent pantothenic acid, riboflavin, thiamine, vitamin B6, vitamin B12, vitamin E deficiency.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Other names
Genestra Brands Femagen Capsules
Licence holder
Seroyal International
NPN or DIN-HM
80023503
Status
Inactive licence
Licence date
25 January 2011
Revision date
11 December 2020
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80023503

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vitex agnus-castus
    Read the warning, when it applies and the studies cited

    CHASTE TREE - VITEX AGNUS-CASTUS

    Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).

    Sources cited by Health Canada (4)
    • Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Contraindications

    Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).

    Sources cited by Health Canada (9)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
    • Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Health Canada monograph dated 28 March 2024

  • Arctostaphylos uva-ursi
    Read the warning, when it applies and the studies cited

    Bearberry - Arctostaphylos Uva-Ursi

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Applies to products providing 60 milligrams or more of dried leaves and/or products providing 20 milligrams or more of Arbutin, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder, fever, painful urination (dysuria), spasms, or blood in urine (EMA 2018; Duke 2002; Newall 1996).

    Sources cited by Health Canada (2)
    • EMA 2018: EMA/HMPC/750269/2016. European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2018 January 30. [Accessed 2024 June 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf
    • Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A guide for health-care professionals. London (GB): The Pharmaceutical Press; 1996.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant or breastfeeding (EMA 2018; Brinker 2010; ESCOP 2003; WHO 2002; Blumenthal 2000; Mills and Bone 2000; Bradley 1992).

    Sources cited by Health Canada (8)
    • Blumenthal M, Goldberg A, Brinckmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • Bradley PR, editor. British Herbal Compendium Volume 1: A Handbook of Scientific Information on Widely Used Plant Drugs - Companion Volume 1 of the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2018: EMA/HMPC/750269/2016. European Union herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2018 January 30. [Accessed 2024 June 11]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-arctostaphylos-uva-ursi-l-spreng-folium-revision-2_en.pdf
    • ESCOP 2003: European Scientific Cooperative of Phytotherapy. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition completely revised and expanded. Exeter (GB): European Scientific Cooperative on Phytotheraphy; 2003.
    • Mills S, Bone K. Principles and Practice of Phytotherapy, Modern Herbal Medicine. Edinburg (GB): Churchill LYes Soivingston; 2000.
    • WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 3. Geneva (CH): World Health Organization; 2002.
    • OMS 2002: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 3. Genève (CH): Organisation mondiale de la santé; 2002.

    Health Canada monograph dated 30 January 2026

  • Eleutherococcus senticosus
    Read the warning, when it applies and the studies cited

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Route of administration: Oral (ESCOP 2003; Bradley 1992)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Contraindications

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    Sources cited by Health Canada (5)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.

    Health Canada monograph dated 31 October 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Photograph the packaging

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Genestra Brands Femagen PMS Capsules (Seroyal International): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80023503-genestra-brands-femagen-pms-capsules, updated 11 December 2020.

List recorded in 2020. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line